Dainippon Sumitomo Pharma America, Inc. (DSPA), a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd. (DSP), submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lurasidone, an investigational atypical antipsychotic agent for the treatment of schizophrenia. The application, submitted on December 30, 2009, includes data from more than 40 clinical studies ...
Posted by Vyvanse In the News on at
Filed under Vyvanse News · Tagged with Antipsychotic Agent, Dainippon Sumitomo, Drug Application, Dsp, Dspa, Fda, Fda News, Food And Drug, Food And Drug Administration, Food And Drug Administration Fda, Lurasidone, Nda, Pharma, Schizophrenia, Subsidiary, Sumitomo, Treatment Of Schizophrenia
The U.S. Food and Drug Administration today approved Lysteda tablets (tranexamic acid), the first non-hormonal product cleared to treat heavy menstrual bleeding (menorrhagia). Lysteda works by stabilizing a protein that helps blood to clot.
